This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

'Fast Money' Recap: No 'All Clear' for the Markets Yet

On gold, Kelly reiterated that he's surprised by its price reaction to all of the issues in Washington. With negative real-interest rates and ongoing quantitative easing, he concluded that the market is incorrectly pricing gold.

Merck (MRK) was the first stock on the show's "Pops & Drops" segment. Nathan said the job slashing is good for the company and bad for the labor market.

McKesson (MCK) jumped 2.5% and Khouw said the stock is near the upper end of its historical valuation range. He advised using this pop to take some profits.

Chicago Bridge & Iron (CBI) popped 3%. Adami said the stock is not overly valued and thinks investors can stay long.

Walgreen (WAG) moved up 4% on Tuesday and Lebenthal said its earnings report shows consumers are starting open their wallets and spend some money.

H&R Block (HRB) popped 4.5%. Kelly said the company should benefit from the Affordable Care Act. He advised traders on the long side to use $26 as their stop-loss.

Ford (F) was the featured stock on the show's "Street Fight" segment. Lebenthal defended the stock, saying the global economic recovery is helping to drive demand. He added Ford is undervalued, has a solid dividend yield and builds high-demand vehicles.

Kelly disagreed, arguing the company's inventories continue to increase and so do the incentives, and incentives should not be increasing if demand remained strong. He added that industry sales growth is starting to slow and it's time to take profits after the big run.

Yaron Werber, director and senior analyst at Citigroup, was a guest on the show and said the Food and Drug Administration will remain open because of surplus funding, which will allow late-stage drug testing to continue. However, early-stage applications will not be accepted by the FDA if the government shutdown lasts for too long. Ultimately, the longer the shutdown lasts, the bigger effect it will eventually have on the biotech sector.

Lions Gate Entertainment's (LGF) CEO Michael Burns was a guest on the show and said it's a good sign that roughly three-quarters of its online tickets sold out for its upcoming film The Hunger Games: Catching Fire. He added that he expects this film, the second of the trilogy, to do much better internationally than the first film, which brought in about $280 million from overseas.

Nathan said sales aren't growing as much as they should and investors should not buy into the stock at current levels.

For their final trades, Kelly said to buy the iShares MSCI Emerging Markets ETF (EEM) with a stop-loss at $40. Nathan said he was a buyer of Exxon Mobil (XOM) with a stop-loss at $86. Khouw said to sell upside calls against a long Lions Gate Entertainment position, Lebenthal was buying Corning (GLW) and Adami was a buyer of Mylan (MYL).

-- Written by Bret Kenwell in Petoskey, Mich.

Follow TheStreet.com on Twitter and become a fan on Facebook.

Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter. Focuses on short-to-intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,067.56 -5.27 -0.25%
NASDAQ 4,791.63 +4.3130 0.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs